NCT05653518View on ClinicalTrials.gov

Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 9, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Type 1 Diabetes
Interventions
DEVICE

Tandem t:slim X2 with Control-IQ Technology

FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM

DEVICE

Sensor augmented pump (SAP) therapy

Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump

Trial Locations (1)

22903

RECRUITING

University of Virginia Health System, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER